Post-earnings recap
Reported
Thu, May 2, 2024
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Aurinia Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise. However, the stock reacted negatively, declining by 0.58%. The lack of revenue figures and guidance may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.07 | N/A | +58.08% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.